nach oben

Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen

Erschienen in:

04.03.2022 | Originalien

Spondyloarthritiden im Kindes- und Erwachsenenalter

verfasst von: Dr. Toni Hospach, Gerd Horneff, Denis Poddubnyy

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Während sich die axiale Spondyloarthritis im Erwachsenenalter (SpAE) initial häufig mit einer Sakroiliitis manifestiert gilt dies nicht für die Enthesitis-assoziierte Arthritis (EAA) mit Beginn im Kindes-und Jugendalter. Klassischerweise beginnt die EAA mit peripherer Arthritis, und nur ein Teil geht in eine jSpA (juvenile Spondyloarthritis)/SpAE über. Die zur Klassifikation der SpAE und der EAA verwendeten Kriterien werden aktuell validiert bzw. neu überarbeitet. Dabei ist für die EAA erstmals auch die Bildgebung inkludiert. Therapeutisch werden bei beiden Erkrankungen initial NSAR (nichtsteroidale Antirheumatika) eingesetzt, gefolgt von Biologika bzw. synthetischen zielgerichteten krankheitsmodifizierenden Medikamenten bei refraktären Verläufen. Steroide sollten in der Langzeitbehandlung vermieden werden. Zur optimalen Transition und Weiterbetreuung im Erwachsenenalter ist eine enge Kooperation zwischen internistischen und pädiatrischen Rheumatologen notwendig.

Vorheriger Artikel Editorial

Nächster Artikel Hüftfrakturinzidenz und Lockdown: Gibt es Zusammenhänge?

Petty RE et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMed

Goirand M et al (2018) Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol Online J 16(1):21PubMedPubMedCentral

Martini A et al (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol 46(2):190–197PubMed

Porter D, Basu N, Siebert S (2020) Classification criteria: time for a rethink? Ann Rheum Dis 79(10):1264–1266PubMed

Poddubnyy D (2020) Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford) 59(4):iv6–iv17

Minden K et al (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46(9):2392–2401PubMed

Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 64(9):1415–1422

Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the german spondyloarthritis inception cohort. Arthritis Rheum 60(3):717–727PubMed

Dougados M et al (2001) Efficacy of celecoxib, a cyclooxygenase 2‑specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44(1):180–185PubMed

10.

Gomez KS et al (1997) Juvenile onset ankylosing spondylitis—more girls than we thought? J Rheumatol 24(4):735–737PubMed

11.

Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84PubMed

12.

Brown MA et al (1997) Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 40(10):1823–1828PubMed

13.

Sieper J, Poddubnyy D (2020) Pathogenesis of spondylarthritis : relevance for treatment. Z Rheumatol 79(1):5–12PubMed

14.

Gmuca S et al (2017) Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthritis Res Ther 19(1):84PubMedPubMedCentral

15.

Weiss PF et al (2011) Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res 63(9):1307–1312

16.

Burgos-Vargas R (2012) The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: a critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol Online J 10(1):14PubMedPubMedCentral

17.

Chen HA et al (2012) Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol 39(5):1013–1018PubMed

18.

Olivieri I et al (2012) Low frequency of axial involvement in southern Italian Caucasian children with HLA-B27 positive juvenile onset undifferentiated spondyloarthritis. Clin Exp Rheumatol 30(2):290–296PubMed

19.

Weiss PF et al (2011) Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken) 63(9):1307–1312

20.

Burgos-Vargas R, Vazquez-Mellado J (1995) The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 38(6):835–844PubMed

21.

Weiss PF et al (2016) Assessment of sacroiliitis at diagnosis of juvenile spondyloarthritis by radiography, magnetic resonance imaging, and clinical examination. Arthritis Care Res 68(2):187–194

22.

Stoll ML et al (2010) Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 37(11):2402–2408PubMedPubMedCentral

23.

Flatø B et al (2006) Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 54(11):3573–3582PubMed

24.

Pagnini I et al (2010) Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 37(11):2395–2401PubMed

25.

Terslev L et al (2014) Defining enthesitis in spondyloarthritis by ultrasound: results of a Delphi process and of a reliability reading exercise. Arthritis Care Res (Hoboken) 66(5):741–748

26.

Lopez-Medina C et al (2021) Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 7(1):e1450. https://doi.org/10.1136/rmdopen-2020-001450CrossRefPubMedPubMedCentral

27.

Heiligenhaus A et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019

28.

Marino A et al (2020) Juvenile spondyloarthritis: focus on uveitis. Pediatr Rheumatol Online J 18(1):70PubMedPubMedCentral

29.

Walscheid K et al (2020) Enthesitis-related arthritis: prevalence and complications of associated uveitis in children and adolescents from a population-based nation-wide study in Germany. J Rheumatol 15(191085):191085

30.

Monnet D et al (2004) Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 111(4):802–809PubMed

31.

Rademacher J, Poddubnyy D, Pleyer U (2020) Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis 12:1759720x20951733PubMedPubMedCentral

32.

Mielants H et al (1993) Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy—a prospective study. J Rheumatol 20(9):1567–1572PubMed

33.

Redeker I et al (2020) The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. Ther Adv Musculoskelet Dis 12:1759720x20972610PubMedPubMedCentral

34.

Giani T et al (2020) Usefulness of magnetic resonance enterography in detecting signs of sacroiliitis in young patients with inflammatory bowel disease. Pediatr Rheumatol Online J 18(1):42PubMedPubMedCentral

35.

Stoll ML, Punaro M, Patel AS (2011) Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. J Rheumatol 38(10):2274–2275PubMedPubMedCentral

36.

Meier K et al (2020) Skin manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 12:1759720x20975915PubMedPubMedCentral

37.

Feld J et al (2020) Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology (Oxford) 59(6):1340–1346

38.

Rudwaleit M et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527PubMed

39.

Maksymowych WP et al (2019) MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Ann Rheum Dis 78(11):1550–1558PubMed

40.

Baraliakos X et al (2020) Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged 〈45 years. Ann Rheum Dis 79(2):186–192PubMed

41.

Maksymowych WP et al (2020) Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. Ann Rheum Dis 79(7):935–942PubMed

42.

Witte T et al (2020) IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. Clin Exp Rheumatol 38(6):1127–1131PubMed

43.

Rieter JF et al (2016) The many shades of enhancement: timing of post-gadolinium images strongly influences the scoring of juvenile idiopathic arthritis wrist involvement on MRI. Pediatr Radiol 46(11):1562–1567PubMed

44.

Ording Muller LS et al (2013) MRI of the wrist in juvenile idiopathic arthritis: erosions or normal variants? A prospective case-control study. Pediatr Radiol 43(7):785–795PubMed

45.

Brophy S et al (2002) The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29(6):1236–1243PubMed

46.

Weber U et al (2015) Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 74(6):985–992PubMed

47.

Vendhan K et al (2014) Inflammatory changes of the lumbar spine in children and adolescents with enthesitis-related arthritis: magnetic resonance imaging findings. Arthritis Care Res (Hoboken) 66(1):40–46

48.

Weiss PF, Roth J (2020) Juvenile-versus adult-onset spondyloarthritis: similar, but different. Rheum Dis Clin North Am 46(2):241–257PubMed

49.

Windschall D, Malattia C (2020) Ultrasound imaging in paediatric rheumatology. Best Pract Res Clin Rheumatol 34(6):101570. https://doi.org/10.1016/j.berh.2020.101570CrossRefPubMed

50.

Weiss PF, Chauvin NA (2020) Imaging in the diagnosis and management of axial spondyloarthritis in children. Best Pract Res Clin Rheumatol 34(6):101596. https://doi.org/10.1016/j.berh.2020.101596CrossRefPubMed

51.

Jousse-Joulin S et al (2011) Ultrasonography for detecting enthesitis in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 63(6):849–855

52.

Kehl AS, Corr M, Weisman Review MH (2016) Enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol 68(2):312–322PubMedPubMedCentral

53.

Herregods N et al (2015) Diagnostic value of MRI features of sacroiliitis in juvenile spondyloarthritis. Clin Radiol 70(12):1428–1438PubMed

54.

Kiltz U et al (2020) Is it possible to delegate medical services to qualified nurses specialized in rheumatology when evaluating patients with suspicion of ankylosing spondylitis?-Results of the PredAS study. Z Rheumatol 79(8):729–736. https://doi.org/10.1007/s00393-020-00838-8CrossRefPubMedPubMedCentral

55.

Poddubnyy D, Sieper J (2020) Treatment of axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep 22(9):47PubMedPubMedCentral

56.

Althoff CE et al (2016) Comparison of clinical examination versus whole-body magnetic resonance imaging of enthesitis in patients with early axial spondyloarthritis during 3 years of continuous etanercept treatment. J Rheumatol 43(3):618–624PubMed

57.

Machado P et al (2011) Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53PubMed

58.

Heuft-Dorenbosch L et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132PubMedPubMedCentral

59.

Maksymowych WP et al (2009) Development and validation of the spondyloarthritis research consortium of Canada (SPARCC) enthesitis index. Ann Rheum Dis 68(6):948–953PubMed

60.

Redeker I et al (2020) Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis. Z Rheumatol 79(1):85–94

61.

Weiss PF, Vossough A, Chauvin NA (2016) Reply. Arthritis Rheumatol 68(1):263–264PubMedPubMedCentral

62.

Proft F et al (2020) Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. Semin Arthritis Rheum 50(5):1015–1021PubMed

63.

Weiss PF et al (2020) Spondyloarthritis research consortium of Canada sacroiliac joint inflammation and structural scores: change score reliability and recalibration utility in children. Arthritis Res Ther 22(1):58PubMedPubMedCentral

64.

Marino A et al (2020) Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies. Expert Opin Pharmacother 29:1–8

65.

Horneff G et al (2015) Efficacy and safety of etanercept in enthesitis-related arthritis juvenile idiopathic arthritis: results from a phase 3 randomized double-blind study. Arthritis Rheumatol 67(8):2240–2249. https://doi.org/10.1002/art.39145CrossRefPubMed

66.

Hugle B et al (2014) Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 32(3):424–431PubMed

67.

Kiltz U, Braun J (2020) Current treatment of axial spondylarthritis : clinical efficacy. Z Rheumatol 79(1):13–22PubMed

68.

Rohekar S et al (2015) 2014 update of the Canadian rheumatology association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: specific management recommendations. J Rheumatol 42(4):665–681PubMed

69.

Haibel H et al (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73(1):243–246PubMed

70.

Chamlati R et al (2020) Image guided sacroiliac joint corticosteroid injections in children: an 18-year single-center retrospective study. Pediatr Rheumatol Online J 18(1):52PubMedPubMedCentral

71.

Fischer T et al (2003) Sacroiliitis in children with spondyloarthropathy: therapeutic effect of CT-guided intra-articular corticosteroid injection. Rofo 175(6):814–821PubMed

72.

Huppertz HI et al (1995) Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr 127(2):317–321PubMed

73.

Breit W et al (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27(11):2696–2702PubMed

74.

Burgos-Vargas R et al (2002) A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 61(10):941–942PubMedPubMedCentral

75.

Ruperto N et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50(7):2191–2201PubMed

76.

Chen J et al (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD4524

77.

van der Heijde D et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991PubMed

78.

Poddubnyy D et al (2020) Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. Rheumatology (Oxford) 59(12):3798–3806

79.

Horneff G et al (2012) Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 14(5):R230PubMedPubMedCentral

80.

Weiss PF et al (2018) Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: the first year after diagnosis. J Rheumatol 45(1):107–114PubMed

81.

Ramanan AV et al (2017) Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 376(17):1637–1646PubMed

82.

Hyams JS et al (2012) Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 143(2):365–374.e2PubMed

83.

Bray TJP et al (2019) Sacroiliac joint ankylosis in young spondyloarthritis patients receiving biologic therapy: observation of serial magnetic resonance imaging scans. Arthritis Rheumatol 71(4):594–598PubMedPubMedCentral

84.

Koo BS et al (2020) Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis 79(10):1327–1332PubMed

85.

Baeten D et al (2015) Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548PubMed

86.

Deodhar A et al (2021) Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. Arthritis Rheumatol 73(1):110–120. https://doi.org/10.1002/art.41477CrossRefPubMed

87.

van der Heijde D et al (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392(10163):2441–2451PubMed

88.

Deodhar A et al (2020) Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 395(10217):53–64PubMed

89.

Dougados M et al (2020) Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST‑V and COAST-W). Ann Rheum Dis 79(2):176–185PubMed

90.

Erdes S et al (2020) Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol 38(1):27–34PubMed

91.

van der Heijde D et al (2020) Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis 79(5):595–604PubMed

92.

Akkoc N, Khan MA (2021) JAK inhibitors for axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep 23(6):34PubMed

93.

van der Heijde D et al (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340–1347PubMed

94.

van der Heijde D et al (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392(10162):2378–2387PubMed

95.

van der Heijde D et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 394(10214):2108–2117PubMed

96.

Deodhar A et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004–1013. https://doi.org/10.1136/annrheumdis-2020-219601CrossRef

97.

Flatø B et al (2002) The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis. Arthritis Rheum 46(4):986–994PubMed

98.

Berntson L et al (2008) HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol 35(10):2055–2061PubMed

99.

Feldtkeller E et al (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66PubMed

100.

Gensler LS et al (2008) Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 67(2):233–237PubMed

101.

Baek HJ et al (2002) Juvenile onset ankylosing spondylitis (JAS) has less severe spinal disease course than adult onset ankylosing spondylitis (AAS): clinical comparison between JAS and AAS in Korea. J Rheumatol 29(8):1780–1785PubMed

102.

Kim TJ et al (2016) Comparison on radiographic progression for 5 years between juvenile onset ankylosing spondylitis and adult onset ankylosing spondylitis: an observational study of the Korean SpondyloArthropathy registry (OSKAR) data. Clin Exp Rheumatol 34(4):668–672PubMed

103.

Beukelman T et al (2011) 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465–482

104.

Mease PJ et al (2020) Characterization of patients with axial spondyloarthritis by enthesitis presence: data from the corrona psoriatic arthritis/spondyloarthritis registry. ACR Open Rheumatol 2(7):449–456PubMedPubMedCentral

105.

Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6):S16–22PubMed

106.

Prati C et al (2011) Mortality in spondylarthritis. Joint Bone Spine 78(5):466–470PubMed

107.

Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925PubMed

108.

Hospach T et al (2018) Protokolle zur Klassifikation, Überwachung und Therapie in der Kinderrheumatologie (PRO-KIND): Enthesitis-assoziierte Arthritis. Arthritis Rheuma 38(02):132–140. https://doi.org/10.1055/s-0038-1649293CrossRef

109.

Oommen P et al (2019) Therapie der „Juvenilen idiopathischen Arthritis“. https://www.awmf.org/leitlinien/detail/ll/027-020.html. Zugegriffen: 28. Juli 2021 (Reg. Nr 027-020)

Titel: Spondyloarthritiden im Kindes- und Erwachsenenalter
verfasst von: Dr. Toni Hospach
Gerd Horneff
Denis Poddubnyy
Publikationsdatum: 04.03.2022
Verlag: Springer Vienna
Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 1/2022
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI: https://doi.org/10.1007/s41970-022-00184-y

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

News-Screen Orthopädie & Traumatologie

News-Screen Osteologie

Hüftfrakturinzidenz und Lockdown: Gibt es Zusammenhänge?

Mitteilungen der ÖGKM

News-Screen Rheumatologie

Editorial